The Lupus Research Alliance (LRA) announced the inaugural recipients of a new Targeted Research Program on Engineered Cell Therapies for Lupus (TRP-ECT) to support the development of safe and accessible next-gen engineered cell therapies for people with lupus.
The LRA, the largest non-governmental, nonprofit funder of lupus research worldwide, established the program to build on the promise already shown for engineered cell therapies in treating and potentially curing lupus, including a clinical trial showing complete remission among participants treated with CD19 CAR-T cells who had not responded to previous treatments.
The TRP-ECT provides funding for two types of studies: preclinical studies, including discovery and translational projects, each of which will be supported with up to $300,000 over two years, and ancillary studies to ongoing or completed clinical trials, which will each receive up to $600,000 over two years.
The LRA awarded funding to eight preclinical recipients and four ancillary study recipients.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!